| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence to surveillance guidelines after radical cystectomy: A population-based analysis
|
Ehdaie, Behfar
|
|
2014
|
32 |
6 |
p. 779-784
6 p.
|
artikel
|
| 2 |
Association of reimbursement policy and urologists׳ characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer 1 1 Funding: This work was supported by the American Cancer Society, Intramural Research Department, Atlanta, GA.
|
Quek, Ruben G.W.
|
|
2014
|
32 |
6 |
p. 748-760
13 p.
|
artikel
|
| 3 |
Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer
|
James, Andrew C.
|
|
2014
|
32 |
6 |
p. 815-819
5 p.
|
artikel
|
| 4 |
Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up
|
Forauer, Andrew R.
|
|
2014
|
32 |
6 |
p. 869-876
8 p.
|
artikel
|
| 5 |
Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology? 1 1 Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.
|
Abd-Alazeez, Mohamed
|
|
2014
|
32 |
6 |
p. 741-747
7 p.
|
artikel
|
| 6 |
Can urinary nerve growth factor distinguish high-grade prostate cancer?
|
Ergin, Giray
|
|
2014
|
32 |
6 |
p. 940-
1 p.
|
artikel
|
| 7 |
CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition
|
Liang, Wu
|
|
2014
|
32 |
6 |
p. 855-863
9 p.
|
artikel
|
| 8 |
Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma
|
Zhang, Qi
|
|
2014
|
32 |
6 |
p. 798-805
8 p.
|
artikel
|
| 9 |
Commentary on “African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them?” Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD.
|
Eggener, Scott
|
|
2014
|
32 |
6 |
p. 936-
1 p.
|
artikel
|
| 10 |
Commentary on “Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation.” Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
|
Boorjian, Stephen
|
|
2014
|
32 |
6 |
p. 934-935
2 p.
|
artikel
|
| 11 |
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI.
|
Eggener, Scott
|
|
2014
|
32 |
6 |
p. 936-937
2 p.
|
artikel
|
| 12 |
Commentary on “Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.” Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY.
|
Eggener, Scott
|
|
2014
|
32 |
6 |
p. 935-936
2 p.
|
artikel
|
| 13 |
Commentary on “Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer.” Joh HK, Giovannucci EL, Bertrand KA, Lim S, Cho E, Department of Medicine, Seoul National University College of Medicine, Seoul, South Korea.
|
Boorjian, Stephen
|
|
2014
|
32 |
6 |
p. 933-934
2 p.
|
artikel
|
| 14 |
Commentary on “Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010.” Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.
|
Boorjian, Stephen
|
|
2014
|
32 |
6 |
p. 932-933
2 p.
|
artikel
|
| 15 |
Commentary on “The association between physical activity and renal cancer: Systematic review and meta-analysis.” Behrens G, Leitzmann MF, Department of Epidemiology and Preventive Medicine, Regensburg University Medical Center, Regensburg, Germany.
|
Boorjian, Stephen
|
|
2014
|
32 |
6 |
p. 932-
1 p.
|
artikel
|
| 16 |
Defining the level of evidence for technology adoption in the localized prostate cancer pathway
|
Valerio, Massimo
|
|
2014
|
32 |
6 |
p. 924-930
7 p.
|
artikel
|
| 17 |
Disease-specific survival after radical lymphadenectomy for penile cancer: Prediction by lymph node count and density 1 1 This work was supported by the Science and Technology Foundation of the Guangdong Province (2012B031800079 to H. Han). 2 Zai-shang Li and Kai Yao contributed equally to this article.
|
Li, Zai-shang
|
|
2014
|
32 |
6 |
p. 893-900
8 p.
|
artikel
|
| 18 |
Editorial Board
|
|
|
2014
|
32 |
6 |
p. i-
1 p.
|
artikel
|
| 19 |
Editorial Comment on “Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection”
|
Milojevic, Bogomir
|
|
2014
|
32 |
6 |
p. 938-
1 p.
|
artikel
|
| 20 |
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer 1 2 1 Funding/support: This research was supported and funded through the Center for Prostate Disease Research (CPDR), the Uniformed Services University of the Health Sciences, the Intramural Research Program of the Clinical Research Center, and the National Cancer Institute, National Institutes of Health, Bethesda, MD, US. 2 Presentations: These data were presented at the 2012 Annual Meeting of the American Urological Association in Atlanta, GA.
|
Metwalli, Adam R.
|
|
2014
|
32 |
6 |
p. 761-768
8 p.
|
artikel
|
| 21 |
hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor
|
Dong, Xiao
|
|
2014
|
32 |
6 |
p. 885-892
8 p.
|
artikel
|
| 22 |
Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method
|
Shinmei, Shunsuke
|
|
2014
|
32 |
6 |
p. 769-778
10 p.
|
artikel
|
| 23 |
Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors 1 1 Grant support: The Swedish Cancer Society, the Swedish research council, the Nilsson Cancer foundation, the BioCARE Strategic Cancer Research program, the Lund Medical Faculty, and FoU Landstinget Kronoberg and Södra Regionvårdnämnden.
|
Sjödahl, Gottfrid
|
|
2014
|
32 |
6 |
p. 791-797
7 p.
|
artikel
|
| 24 |
Introduction—Targeting the lesion, not the organ
|
Ahmed, Hashim U.
|
|
2014
|
32 |
6 |
p. 901-902
2 p.
|
artikel
|
| 25 |
Masthead
|
|
|
2014
|
32 |
6 |
p. IFC-
1 p.
|
artikel
|
| 26 |
Micropapillary bladder cancer: Current treatment patterns and review of the literature
|
Willis, Daniel L.
|
|
2014
|
32 |
6 |
p. 826-832
7 p.
|
artikel
|
| 27 |
miR-145 inhibits invasion of bladder cancer cells by targeting PAK1 1 1 This study was supported by National Natural Science Foundation of China (No. 81372279 to P. Guo).
|
Kou, Bo
|
|
2014
|
32 |
6 |
p. 846-854
9 p.
|
artikel
|
| 28 |
National trends in the utilization of robotic-assisted radical cystectomy: An analysis using the Nationwide Inpatient Sample
|
Monn, M. Francesca
|
|
2014
|
32 |
6 |
p. 785-790
6 p.
|
artikel
|
| 29 |
Neutrophil-lymphocyte ratio evaluation in patients undergoing radical cystectomy
|
Agilli, Mehmet
|
|
2014
|
32 |
6 |
p. 939-
1 p.
|
artikel
|
| 30 |
Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma 1 Present address: Department of Urology, University Hospital Frankfurt, Germany. 2 Equal contributions.
|
Schneider, Meike
|
|
2014
|
32 |
6 |
p. 877-884
8 p.
|
artikel
|
| 31 |
Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? 1 Contributed equally to manuscript.
|
Kaimakliotis, Hristos Z.
|
|
2014
|
32 |
6 |
p. 833-838
6 p.
|
artikel
|
| 32 |
Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration 1 Co-first authors.
|
Fradet, Vincent
|
|
2014
|
32 |
6 |
p. 839-845
7 p.
|
artikel
|
| 33 |
Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy
|
Koie, Takuya
|
|
2014
|
32 |
6 |
p. 820-825
6 p.
|
artikel
|
| 34 |
Surgeons’ preferences and practice patterns regarding intraoperative frozen section during partial nephrectomy
|
Sidana, Abhinav
|
|
2014
|
32 |
6 |
p. 864-868
5 p.
|
artikel
|
| 35 |
Survey Section Editorial Board
|
|
|
2014
|
32 |
6 |
p. 931-
1 p.
|
artikel
|
| 36 |
Table of Contents
|
|
|
2014
|
32 |
6 |
p. ii-v
nvt p.
|
artikel
|
| 37 |
Target ablation—Image-guided therapy in prostate cancer 1 1 Arnaud Marien is supported by a Grant from ARC. Inderbir Gill is a paid consultant for Hansen Medical and EDAP. Osamu Ukimura is an Advisory Board Member of SonaCare Medical LLC. All others have nothing to disclose.
|
Marien, Arnaud
|
|
2014
|
32 |
6 |
p. 912-923
12 p.
|
artikel
|
| 38 |
Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy
|
Sonn, Geoffrey A.
|
|
2014
|
32 |
6 |
p. 903-911
9 p.
|
artikel
|
| 39 |
The future of quality in urologic oncology: Evaluating the horizon of surgical standards
|
|
|
2014
|
32 |
6 |
p. 735-740
6 p.
|
artikel
|
| 40 |
The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer
|
Hayden, Annette
|
|
2014
|
32 |
6 |
p. 806-814
9 p.
|
artikel
|
Tijdschrift beschrijving